-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Aigen Investment Management LP Makes New $2.46 Million Investment in Sanofi (NASDAQ:SNY)
Aigen Investment Management LP Makes New $2.46 Million Investment in Sanofi (NASDAQ:SNY)
Aigen Investment Management LP acquired a new position in Sanofi (NASDAQ:SNY – Get Rating) in the third quarter, HoldingsChannel.com reports. The fund acquired 64,773 shares of the company's stock, valued at approximately $2,463,000.
A number of other large investors have also modified their holdings of SNY. FMR LLC raised its position in shares of Sanofi by 1.3% during the 2nd quarter. FMR LLC now owns 18,715,053 shares of the company's stock worth $936,314,000 after purchasing an additional 234,158 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Sanofi by 162.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,244,354 shares of the company's stock worth $862,735,000 after purchasing an additional 10,684,509 shares during the last quarter. Invesco Ltd. raised its position in shares of Sanofi by 2.3% during the 1st quarter. Invesco Ltd. now owns 5,077,848 shares of the company's stock worth $260,697,000 after purchasing an additional 112,404 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company's stock worth $172,611,000 after purchasing an additional 2,468,271 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of Sanofi by 0.8% during the 1st quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company's stock worth $170,536,000 after purchasing an additional 25,457 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.
Get Sanofi alerts:Sanofi Stock Performance
Sanofi stock opened at $45.86 on Tuesday. The firm has a 50 day simple moving average of $47.91 and a 200-day simple moving average of $43.28. Sanofi has a 1-year low of $36.91 and a 1-year high of $58.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. The stock has a market cap of $115.64 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.
Analysts Set New Price Targets
SNY has been the subject of several research analyst reports. Morgan Stanley restated an "overweight" rating on shares of Sanofi in a research report on Tuesday, December 13th. TheStreet upgraded shares of Sanofi from a "c+" rating to a "b-" rating in a report on Friday, December 2nd. StockNews.com started coverage on shares of Sanofi in a report on Wednesday, October 12th. They issued a "strong-buy" rating for the company. Barclays cut their price objective on shares of Sanofi from €105.00 ($112.90) to €85.00 ($91.40) and set an "equal weight" rating for the company in a report on Friday, October 14th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, December 16th. They issued a "buy" rating for the company. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $102.88.About Sanofi
(Get Rating)
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
Further Reading
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Why Is Wall Street Loving Amazon So Much?
- Want to Invest in ChatGPT? Then Buy Microsoft Stock
- Anhui Conch: Opportunity With Cement Solid Cash Flows
- Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
- Is Biotech Immunocore About To Make A 25% Price Move?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Get Rating).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
Aigen Investment Management LP acquired a new position in Sanofi (NASDAQ:SNY – Get Rating) in the third quarter, HoldingsChannel.com reports. The fund acquired 64,773 shares of the company's stock, valued at approximately $2,463,000.
艾根投資管理有限公司在第三季度收購了賽諾菲的新職位 (納斯達克:SNY — 獲得評級), Holdingschannel.com 報導.該基金收購了該公司股票 64,773 股，價值約為 2,463,000 美元。
A number of other large investors have also modified their holdings of SNY. FMR LLC raised its position in shares of Sanofi by 1.3% during the 2nd quarter. FMR LLC now owns 18,715,053 shares of the company's stock worth $936,314,000 after purchasing an additional 234,158 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Sanofi by 162.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,244,354 shares of the company's stock worth $862,735,000 after purchasing an additional 10,684,509 shares during the last quarter. Invesco Ltd. raised its position in shares of Sanofi by 2.3% during the 1st quarter. Invesco Ltd. now owns 5,077,848 shares of the company's stock worth $260,697,000 after purchasing an additional 112,404 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company's stock worth $172,611,000 after purchasing an additional 2,468,271 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of Sanofi by 0.8% during the 1st quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company's stock worth $170,536,000 after purchasing an additional 25,457 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.
許多其他大型投資者也修改了他們對 SNY 的持有量。FMR 有限責任公司在第二季度提高了其在賽諾菲股份的地位 1.3％。在上一季度額外購買 234,158 股股份後，金融有限責任公司現在擁有該公司股票的 18,715,053 股股票，價值 936,314,000 美元。價格牛逼羅聯營公司 MD 在第二季度提出了其在賽諾菲的股份地位 162.9％。T 羅威聯營股份有限公司現在擁有該公司股票的 17,244,354 股價值 862,735,000 美元，在上一季度額外購買 10,684,509 股股票後。景順有限公司於第一季度提高了 2.3% 的賽諾菲股份地位。景順有限公司於上一季額外購入 112,404 股股份後，擁有該公司股票價值 260,697,000 元，現時擁有該公司 5,077,848 股股份。箭街資本有限公司合夥在第一季度上調了其在賽諾菲股份的地位 276.1％。在上一季度額外購買 2,468,271 股股份後，箭街資本有限公司合夥公司股票價值 172,611,000 美元，現在擁有該公司股票的 3,362,112 股股份。最後, 拉扎德資產管理有限責任公司提出了賽諾菲的股份地位 0.8% 在第一季度.在上一季度購買額外的 25,457 股股票後，拉扎德資產管理有限責任公司現在擁有該公司股票的 3,321,721 股價值 170,536,000 美元。機構投資者和對沖基金擁有公司股票的 10.04％。
Sanofi Stock Performance
賽諾菲股票表現
Sanofi stock opened at $45.86 on Tuesday. The firm has a 50 day simple moving average of $47.91 and a 200-day simple moving average of $43.28. Sanofi has a 1-year low of $36.91 and a 1-year high of $58.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. The stock has a market cap of $115.64 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.
賽諾菲股票週二以 45.86 美元開盤。該公司擁有 50 天的簡單移動平均線為 47.91 美元，以及 200 天的簡單移動平均線為 43.28 美元。賽諾菲有一年低點 36.91 美元和一年新高 58.10 美元。該公司的債務與權益比率為 0.22，流動比率為 1.29，快速比率為 0.34。該股的市值為 1,156.5 億美元，股價與盈利比率為 16.21，股價對盈利增長比率為 1.07，測試版為 0.56。
Analysts Set New Price Targets
分析師設定新的價格目標
About Sanofi
關於賽諾菲
(Get Rating)
(取得評分)
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
賽諾菲從事研究, 生產, 和醫藥產品的分銷.它通過以下業務部門運營：藥品，消費者保健和疫苗。藥品部門包括以下全球特許經營權的商業運營：專科護理，糖尿病和心血管，既定的處方產品和仿製品，以及研究，開發和生產活動。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Why Is Wall Street Loving Amazon So Much?
- Want to Invest in ChatGPT? Then Buy Microsoft Stock
- Anhui Conch: Opportunity With Cement Solid Cash Flows
- Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
- Is Biotech Immunocore About To Make A 25% Price Move?
- 獲取有關賽諾菲（SNY）的研究報告的免費副本
- 為什麼華爾街愛亞馬遜如此之多？
- 想要投資聊天研究計劃嗎？然後購買微軟股票
- 安徽海螺：水泥固體現金流的機遇
- 默克股票在盈利後拋售後是否可以買入？
- 是生物技術免疫即將做出 25% 價格走勢?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Get Rating).
想看看還有哪些對沖基金持有 SNY？ 訪問 Holdingschannel.com 以獲取賽諾菲（納斯達克：SNY-獲取評級）的最新文件和內幕交易。
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
接收賽諾菲日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Sanofi 及相關公司的最新新聞和分析師評級的簡明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧